In patients with advanced NSCLC harboring sensitizing EGFR mutations, EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment was significantly better effective than conventional chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.